Andere Sprachen PharmAbcine Inc.

Aktien

A208340

KR7208340000

A208340

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 19.01.2024			% 5 Tage	% 1. Jan.
2’915 ^KRW	-8.91%		-.--%	-22.27%

24.01.	PharmAbcine Inc. gibt bekannt, dass der erste Patient in der klinischen Phase 1a/b-Studie von PMC-309 in Kombination mit KEYTRUDA®? (Pembrolizumab) bei Patienten mit fortgeschrittenen oder metastasierten soliden Tumoren	CI
2023	Pharmabcine, Inc. Das Safety Review Committee (SRC) genehmigt das Vorrücken zur Dosisstufe 2 der klinischen Studie von PMC-403 bei neovaskulärer altersbedingter Makuladegeneration nach den Sicherheitsdaten der Dosisstufe 1	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology Annual Meeting 2024	23.04.
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA in Patients with Advanced or Metastatic Solid Tumors	24.01.
PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	24.01.
PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	26.12.
PharmAbcine Inc. announced that it has received KRW 30.000001149 billion in funding from Hpbiolab Inc.	01.12.
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data	10.11.
Pharmabcine, Inc. Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-Related Macular Degeneration Following Dose Level 1 Safety Data	09.11.
PharmAbcine Inc. announced that it expects to receive KRW 5.000000492 billion in funding	26.10.23
PharmAbcine Inc. announced extension to the offering period	07.08.23
Yukon Partners Co., Ltd. acquired a 6.2% stake in PharmAbcine Inc. from Yoo Jin San for KRW 4.4 billion	27.07.23
PharmAbcine Inc. announced that it expects to receive KRW 30.000001149 billion in funding	16.06.23
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of its Novel TIE2 Agonistic Antibody in nAMD	23.05.23
PharmAbcine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	15.03.23
Pharmabcine Announces Collaboration Agreement with MSD to Evaluate Anti-Vista Antibody PMC-309 in Combination with Keytruda(R) (Pembrolizumab)	12.12.22
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase 2023 during JPM Week	09.12.22
PharmAbcine Inc.(KOSDAQ:A208340) dropped from S&P Global BMI Index	19.09.22
Pharmabcine Inc. Announces the Positive Results from the GLP Toxicology Study of PMC-403, the Company's Novel TIE2-Activating Antibody	26.04.22
PharmAbcine Inc. Announces the Appointment of Quan Dong Nguyen to its Scientific Advisory Board	26.04.22
PharmAbcine Inc. announced that it has received KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm	15.04.22
PharmAbcine Inc. announced that it expects to receive KRW 10 billion in funding from Kiwoom Asset Management Co., Ltd., Hanyang Securities Co. Ltd., NH Investment & Securities Co., Ltd., Investment Arm and other investors	13.04.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen PharmAbcine Inc.

Aktien

A208340

KR7208340000

A208340

Andere Sprachen

Filter